Clustering of cardiovascular risk factors associated with the insulin resistance syndrome: Assessment by principal component analysis in young hyperandrogenic women

Diabetes Care

Volumn 29, Issue 2, 2006, Pages 372-378

  Zanolin, M Elisabetta ^a   Tosi, Flavia ^a   Zoppini, Giacomo ^a   Castello, Roberto ^a   Spiazzi, Giovanna ^a   Dorizzi, Romolo ^a   Muggeo, Michele ^a   Moghetti, Paolo ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GONADORELIN AGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYPROGESTERONE; INSULIN; TESTOSTERONE; TRIACYLGLYCEROL; URIC ACID; SEX HORMONE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PRINCIPAL COMPONENT ANALYSIS; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASE; GLUCOSE TOLERANCE TEST; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; FEMALE; GLUCOSE TOLERANCE TEST; GONADAL STEROID HORMONES; HUMANS; HYPERANDROGENISM; INSULIN; INSULIN RESISTANCE; METABOLIC SYNDROME X; PRINCIPAL COMPONENT ANALYSIS; RISK FACTORS; TRIGLYCERIDES; URIC ACID;

EID: 33646347664     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.29.02.06.dc05-1478     Document Type: Article

References (54)

1. Reaven GM: Role of insulin resistance in human diseases. Diabetes 37:1595-607, 1988
2. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
3. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP: Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 41:715-722, 1992
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
5. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: finding from the Third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002
6. Meigs JB, D'Agostino RB, Wilson PWF, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome. Diabetes 46:1594-1600, 1997
7. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774-800, 1997
8. Lobo RA, Carmina E: The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132:989-993, 2000
9. Wild RA: Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol 186:35-43, 2002
10. Ovalle F, Azziz R: Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 77:1095-1105, 2002
11. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC: The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20:535-582, 1999
12. Nestler JE: Insulin resistance and the polycystic ovary syndrome: recent advances. Curr Opin Endocrinol Diabetes 7:345-349, 2000
13. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237-252, 2003
14. Hatch R, Rosenfield RL, Kim MH, Tredway D: Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 140:815-830, 1981
15. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA: Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 320:559-565, 1989
16. Rosenfield RL, Ehrmann DA, Barnes RB, Sheikh Z: Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. Ann N Y Acad Sci 687:162-181, 1993
17. Ehrmann DA, Barnes RB, Rosenfield RL: Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 16:322-369, 1995
18. Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, Furlani L, Caputo M, Muggeo M: The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 81:952-960, 1996
19. Travia D, Tosi F, Negri C, Faccini G, Moghetti P, Muggeo M: Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J Clin Endocrinol Metab 80:836-840, 1995
20. Moghetti P, Castello R: New routes in the polycystic ovary syndrome labyrinth: a way out? J Endocrinol Invest 21:648-655, 1998
21. Wild RA: Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 98 (Suppl. 1A):27S-32S, 1995
22. Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, Richmond W, Johnston DG, Franks S: Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol 44:277-284, 1996
23. Legro RS: Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 24:302-312, 2003
24. Holte J, Gennarelli G, Berne C, Bergh T, Lithell H: Elevated ambulatory day-time pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 11:23-28, 1996
25. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, Mattson LA, Crona N, Lundberg PA: Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 57:505-513, 1992
26. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L: Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15:821-826, 1995
27. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS: Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol 37:119-125, 1992
28. Wild RA, Alaupovic P, Parker IJ: Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance. Am J Obstet Gynecol 166:1191-1197, 1992
29. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L: Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52:908-915, 2003
30. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929-1935, 2005
31. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M: Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47:1643-1649, 1998
32. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987
33. Zavaroni I, Bonora E, Pagliara M, Dall'Aglio E, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, Gnudi L, Passeri M, Reaven G: Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 320:502-506, 1989
34. Falkner B, Hulman D, Tannebaum J, Kushner H: Insulin resistance and blood pressure in young black men. Hypertension 16:706-711, 1990
35. Mbanya JCN, Thomas TH, Wilkinson R, Alberti KGMM, Taylor R: Hypertension and hyperinsulinemia: a relation in diabetics but not in essential hypertension. Lancet 1:733-734, 1988
36. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, DeGregorio M, Ravussin E, Knowler WC, Bennett PH, Howard BV, Bogardus C: Racial differences in the relationship with blood pressure and insulin resistance. N Engl J Med 324:733-739, 1991
37. Muller DC, Elahi D, Pratley RE, Tobin JD, Andres R: An epidemiological test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab 76:544-548, 1993
38. Haffner SM, Ferrannini E, Hazuda HP, Stern MP: Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 20:38-45, 1992
39. Franks S, Kiddy D, Sharp P, Singh A, Reed M, Seppala M, Koistinen R, Hamilton-Fairley D: Obesity and polycystic ovary syndrome. Ann N Y Acad Sci 626:201-206, 1991
40. Pasquali R, Casimirri F: The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf) 39:1-16, 1993
41. Holte J: Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style? J Endocrinol Invest 21:589-601, 1998
42. Brown WV: Lipoprotein disorders in diabetes mellitus. Med Clin North Am 78:143-161, 1994
43. Zimmermann S, Phillips RA, Dunaif A, Finegood DT, Wilkenfeld C, Ardeljan M, Gorlin R, Krakoff LR: Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 75:508-513, 1992
44. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS: Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 45:623-629, 1996
45. DeFronzo RA: The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667-687, 1988
46. Barbieri RL, Makris A, Randall RW, Daniels G, Kristner RW, Ryan KJ: Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 62:904-910, 1986
47. Nestler JE, Jakubowicz DJ, De Vargas AF, Brik C, Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83:2001-2005, 1998
48. Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E, Balducci R, Toscano V, Muggeo M: Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 81:881-886, 1996
49. Nestler JE, Powers LP, Matt DW: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72:83-89, 1991
50. Plymate SR, Matej LA, Jones RE: Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 67:460-464, 1988
51. Holmang A, Svedberg J, Jennische E, Bjorntorp P: Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 259:E555-E560, 1990
52. Speiser PW, Serrat J, New MI, Gertner JM: Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 75:1421-1424, 1992
53. Diamond MP, Grainger D, Diamond MC, Sherwin RS, DeFronzo RA: Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab 83:4420-4425, 1998
54. Golden SH, Ding J, Szklo M, Schmidt MI, Duncan BB, Dobs A: Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women. Am J Epidemiol 160:540-548, 2004